KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Equity Income (2017 - 2021)

Historic Equity Income for Biomarin Pharmaceutical (BMRN) over the last 12 years, with Q3 2021 value amounting to $177000.0.

  • Biomarin Pharmaceutical's Equity Income rose 11921.82% to $177000.0 in Q3 2021 from the same period last year, while for Sep 2021 it was -$278000.0, marking a year-over-year increase of 6855.2%. This contributed to the annual value of -$6000.0 for FY2020, which is 9897.79% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Equity Income of $177000.0 as of Q3 2021, which was up 11921.82% from -$175000.0 recorded in Q2 2021.
  • Biomarin Pharmaceutical's 5-year Equity Income high stood at $1.1 million for Q4 2020, and its period low was -$1.4 million during Q1 2021.
  • For the 5-year period, Biomarin Pharmaceutical's Equity Income averaged around -$185533.3, with its median value being -$107000.0 (2018).
  • Its Equity Income has fluctuated over the past 5 years, first surged by 51956.52% in 2019, then tumbled by 165454.55% in 2021.
  • Biomarin Pharmaceutical's Equity Income (Quarter) stood at -$220000.0 in 2017, then surged by 79.09% to -$46000.0 in 2018, then surged by 519.57% to $193000.0 in 2019, then surged by 454.92% to $1.1 million in 2020, then crashed by 83.47% to $177000.0 in 2021.
  • Its Equity Income was $177000.0 in Q3 2021, compared to -$175000.0 in Q2 2021 and -$1.4 million in Q1 2021.